{"id":"der-45-ev","_chembl":{"chemblId":"CHEMBL5944561","moleculeType":null,"molecularWeight":"556.37"},"_fixedAt":"2026-03-30T16:18:42.974411","_dailymed":null,"_scrapedAt":"2026-03-28T02:31:49.363Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122977,"model":"claude-sonnet-4-5-20250929"},"description":"DER 45 EV is an investigational drug developed by Sol-Gel Technologies, Ltd., currently in Phase 2 clinical development. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this time.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"_fixedFields":["pubmed(11)"],"trialDetails":[{"nctId":"NCT00940992","phase":"PHASE2","title":"A Study of DER 45-EV Gel to Treat Rosacea","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2012-01","conditions":"Rosacea","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"recentPublications":[{"date":"2025 Apr 9","pmid":"40152624","title":"High solar-to-hydrogen efficiency in Z-scheme AlN/GaO heterojunctions for visible light water splitting.","journal":"Physical chemistry chemical physics : PCCP"},{"date":"2024 Aug 7","pmid":"39051155","title":"Room Temperature, Twist Angle Independent, Momentum Direct Interlayer Excitons in van der Waals Heterostructures with Wide Spectral Tunability.","journal":"Nano letters"},{"date":"2024 Apr 10","pmid":"38598043","title":"Ab-initio study of strain-tunable g-GaN/BN nanoheterostructure for optoelectronic and photocatalytic applications.","journal":"Journal of molecular modeling"},{"date":"2023 Oct 16","pmid":"37887920","title":"Tuning Interlayer Exciton Emission with TMD Alloys in van der Waals Heterobilayers of Mo(0.5)W(0.5)Se(2) and Its Binary Counterparts.","journal":"Nanomaterials (Basel, Switzerland)"},{"date":"2020 Mar 19","pmid":"32091900","title":"Emerging Nonvalence Anion States of [Isoprene-H·]·H(2)O Accessed via Detachment of OH(-)·Isoprene.","journal":"The journal of physical chemistry. A"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DER 45 EV","genericName":"DER 45 EV","companyName":"Sol-Gel Technologies, Ltd.","companyId":"sol-gel-technologies-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DER 45 EV is a gel being studied as a potential treatment for rosacea. A clinical trial (NCT00940992) is investigating the efficacy of DER 45 EV gel, in comparison to a vehicle gel, in treating rosacea.","enrichmentLevel":2,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}